แสดงรายการชิ้นงานแบบง่าย

Introducing government use of patents on essential medicines in Thailand, 2006-2007 : Policy analysis with key lessons learned and recommendations

dc.contributor.authorSripen Tantivessen_US
dc.contributor.authorNusaraporn Kessomboonen_US
dc.contributor.authorChotiros Laongbuaen_US
dc.contributor.otherInternational Health Policy Programen_US
dc.coverage.spatialThailanden_US
dc.date.accessioned2009-02-24T09:29:14Zen_US
dc.date.accessioned2557-04-17T00:50:26Z
dc.date.available2009-02-24T09:29:14Zen_US
dc.date.available2557-04-17T00:50:26Z
dc.date.issued2551-06en_US
dc.identifier.isbn978-974-16-2131-6en_US
dc.identifier.urihttp://hdl.handle.net/11228/2277en_US
dc.description.abstractIn late 2006 and early 2007, Thailand๛s administration announced its intention to introduce the government use of patents for 3 pharmaceutical products, including 2 antiretrovirals (ARVs): efavirenz and lopinavir/ritonavir combination and drug for heart disease: clopidogrel. According to the Ministry of Public Health (MOPH), this action, with the aim to ensure access to affordable medicines in the public sector, complied with the flexibilities of the Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS). The Thai move prompted rigorous protests and pressure from multinational drug companies and their national governments. At the same time, the use of public health safeguards was praised by international agencies and non-governmental organisations (NGOs). This study assesses the roles of key actors and contextual elements that shaped the processes of policy making and implementation. This analysis suggests that despite continual advocacy by civil society organizations, the idea of enforcing TRIPS flexibilities for essential medicines in Thailand was heightened on the governmental agenda and adopted as a public policy when the new administration took office after a military coup in September 2006. To deal with the opposition from powerful parties, the Thai government sought collaboration with existing alliances of domestic and international NGOs, many of which had experienced campaigning for expansion of HIV/AIDS treatment, including those to encourage the use of TRIPS safeguards for public interests. Diverse strategies were employed by responsible government agencies and civic networks in order to alleviate political pressures and avoid trade retaliations. It could be observed that the government use policy often moved back and forth between the formulation and implementation stage, while limited groups of key stakeholders were involved. While international authorities, such as the World Health Organization (WHO), seemed to be reluctant to participate in the disputes between Thailand and the opponents to the government use policy, global concerns about the unaffordable costs of patented drugs that hampered access to essential health care in the South was beneficial to the Thai action. The potential diffusion of this policy from Thailand to other developing countries triggered substantial tensions between the supporters and opponents of the government use enforcement. The introduction of TRIPS flexibility for medicines in Thailand offers several lessons which may be helpful for resource-poor settings and health advocates coalitions, for example, the roles of public civic networks, relentless advocacy and collective learning among partners, as key factors of success. Policy recommendations derived from this study emphasize the needs for the commitment and leadership of the WHO, in collaboration with other parties, to bridge the gaps between the demands for and access to health products, by fostering intellectual property management frameworks which do not undermine health of the underprivileged.en_US
dc.description.sponsorshipWorld health organization regional officeen_US
dc.format.extent846846 bytesen_US
dc.format.mimetypeapplication/octet-streamen_US
dc.language.isoenen_US
dc.publisherInternational Health Policy Programen_US
dc.rightsInternational Health Policy Programen_US
dc.subjectComsumer Empowermenten_US
dc.subjectAntiretrovirus--Therapeutic Use--Researchen_US
dc.subjectCardiovascular Diseasesen_US
dc.subjectDrugs, Essential--Thailand--Researchen_US
dc.subjectDrugs--Patents--Researchen_US
dc.titleIntroducing government use of patents on essential medicines in Thailand, 2006-2007 : Policy analysis with key lessons learned and recommendationsen_US
dc.typeTechnical Reporten_US
dc.identifier.callnoQV736 S774i 2008 C.1en_US
dc.identifier.callnohe0116en_US
dc.subject.keywordPatentsen_US
dc.subject.keywordPolicy Analysisen_US
dc.subject.keywordEssential Medicinesen_US
.custom.citationSripen Tantivess, Nusaraporn Kessomboon and Chotiros Laongbua. "Introducing government use of patents on essential medicines in Thailand, 2006-2007 : Policy analysis with key lessons learned and recommendations." 2551. <a href="http://hdl.handle.net/11228/2277">http://hdl.handle.net/11228/2277</a>.
.custom.total_download53
.custom.downloaded_today0
.custom.downloaded_this_month0
.custom.downloaded_this_year0
.custom.downloaded_fiscal_year0

ฉบับเต็ม
Icon
ชื่อ: he0116.pdf
ขนาด: 976.8Kb
รูปแบบ: PDF
 

ชิ้นงานนี้ปรากฎในคอลเล็คชั่นต่อไปนี้

แสดงรายการชิ้นงานแบบง่าย